ArticleMycotoxin research2025
Biodetoxification of both AFB1 and ZEN by Bacillus subtilis ZJ-2019-1 in gastrointestinal environment and in mice.
Article in Mycotoxin research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aflatoxin B1 (AFB1) and zearalenone (ZEN) are the most prevalent mycotoxins in production, posing a serious threat to human and animal health. Therefore, it is very urgent to find a safe and efficient method for the biodegradation of these mycotoxins. Our previous study demonstrated that Bacillus subtilis ZJ-2019-1 moderately degrades both mycotoxins in vitro and ZEN in female gilts. In this study, we assessed the effect of B. subtilis ZJ-2019-1 on AFB1 and ZEN degradation in naturally moldy corn gluten meal in a gastrointestinal environment while also evaluating the cytotoxicity of degradation products using the Cell Counting Kit-8 (CCK-8) assay. The efficacy of B. subtilis in degrading mycotoxins was further evaluated by orally administering 5 mg/kg AFB1 and 50 mg/kg ZEN to mice, followed by treatment with B. subtilis ZJ-2019-1 for 15 d. The results showed that B. subtilis ZJ-2019-1 moderately degraded both AFB1 and ZEN present in naturally moldy corn gluten meal in simulated small intestinal fluids, with degradation rates reaching 14.71% for AFB1 and 19.53% for ZEN respectively. Following degradation by B. subtilis ZJ-2019-1, the toxicity of resulting products from both AFB1 and ZEN decreased by 11.68-46.41% and 42.62-59.25%, respectively. Moreover, oral administration of B. subtilis ZJ-2019-1 exhibited remarkable detoxification effects on AFB1 and ZEN in mice, as evidenced by significant restoration of abnormal serum biochemical indices (including aspartate aminotransferase/alanine transaminase, alkaline phosphatase, total cholesterol, etc.) and alleviation of liver, intestine, and uterine damage caused by mycotoxins in mice. These findings indicate that B. subtilis ZJ-2019-1 possesses the ability to moderately degrade both AFB1 and ZEN, making it a promising candidate for biodegrading multi-mycotoxin contaminants in food and feed.
Indexed as
Identifiers
40072827What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.